•  15
    A QALY is [still] a QALY is [still] a QALY?
    with Nikolai Münch and Norbert W. Paul
    BMC Medical Ethics 25 (1): 1-6. 2024.
    Despite clinical evidence of drug superiority, therapeutic modalities, like combination immunotherapy, are mostly considered cost-ineffective due to their high costs per life year(s) gained. This paper, taking an ethical stand, reevaluates the standard cost-effectiveness analysis with that of the more recent justice-enhanced methods and concludes by pointing out the shortcomings of the current methodologies.
  •  16
    Novel immune therapies are increasingly based on the molecular differentiation of disease patterns. The related clinical studies are thus more often characterized by the so-called adaptive study designs (umbrella or basket studies including platform studies), which are continuously adjusted based on novel results. This paper analyses new study designs beyond the often-postulated need for regulation in order to identify ethical problems based on typical structural features and to—whenever possibl…Read more
  •  26
    Resilience beyond reductionism: ethical and social dimensions of an emerging concept in the neurosciences
    with Nikolai Münch, Klaus Lieb, and Norbert W. Paul
    Medicine, Health Care and Philosophy 24 (1): 55-63. 2020.
    Since a number of years, popular and scientific interest in resilience is rapidly increasing. More recently, also neuroscientific research in resilience and the associated neurobiological findings is gaining more attention. Some of these neuroscientific findings might open up new measures to foster personal resilience, ranging from magnetic stimulation to pharmaceutical interventions and awareness-based techniques. Therefore, bioethics should also take a closer look at resilience and resilience …Read more